| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.NEUROSCIENCE.2017.05.024 |
| P8608 | Fatcat ID | release_whr5sm7npbg35okxcbxs5pdgwe |
| P932 | PMC publication ID | 5536977 |
| P698 | PubMed publication ID | 28528968 |
| P2093 | author name string | Wei Qiao Qiu | |
| P2860 | cites work | Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation | Q22008492 |
| Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism | Q24307623 | ||
| p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5 | Q24320432 | ||
| Human islet amyloid polypeptide gene: complete nucleotide sequence, chromosomal localization, and evolutionary history | Q24338152 | ||
| Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells | Q24607640 | ||
| Shared Neuropathological Characteristics of Obesity, Type 2 Diabetes and Alzheimer's Disease: Impacts on Cognitive Decline | Q26784170 | ||
| Epidemiology of Alzheimer disease | Q26865371 | ||
| Brain imaging in Alzheimer disease | Q26996299 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product | Q28138337 | ||
| Receptor pharmacology | Q28298549 | ||
| Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes | Q29615593 | ||
| Amyloid β (Aβ) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways | Q30175699 | ||
| Reduced IGF-1 signaling delays age-associated proteotoxicity in mice | Q30497845 | ||
| An amylin analog used as a challenge test for Alzheimer's disease. | Q33655621 | ||
| Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets | Q69522381 | ||
| Islet amyloid polypeptide (amylin) is expressed in sensory neurons | Q71511640 | ||
| Permeability of the blood-brain barrier to amylin | Q71520909 | ||
| Anti-inflammatory activity of amylin and CGRP in different experimental models of inflammation | Q71756557 | ||
| Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes | Q71809920 | ||
| Islet amyloid polypeptide is expressed in endocrine cells of the gastric mucosa in the rat and mouse | Q72164363 | ||
| Neurotoxicity of human amylin in rat primary hippocampal cultures: similarity to Alzheimer's disease amyloid-beta neurotoxicity | Q72621646 | ||
| Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice | Q77355182 | ||
| IAPP mimic blocks Abeta cytotoxic self-assembly: cross-suppression of amyloid toxicity of Abeta and IAPP suggests a molecular link between Alzheimer's disease and type II diabetes | Q79489683 | ||
| Islet amyloid polypeptide in the islets of Langerhans: friend or foe? | Q33976606 | ||
| On the Relation of Chronic Interstitial Pancreatitis to the Islands of Langerhans and to Diabetes Melutus | Q34019932 | ||
| Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin | Q34089002 | ||
| Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease. | Q34167833 | ||
| Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease | Q34309107 | ||
| Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation | Q34336783 | ||
| Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. | Q34349457 | ||
| Amylin deposition in the brain: A second amyloid in Alzheimer disease? | Q34352928 | ||
| Common core structure of amyloid fibrils by synchrotron X-ray diffraction. | Q34444888 | ||
| Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study | Q34458197 | ||
| Proteolytically inactive insulin-degrading enzyme inhibits amyloid formation yielding non-neurotoxic aβ peptide aggregates | Q34672360 | ||
| Actions of β-amyloid protein on human neurons are expressed through the amylin receptor | Q34760866 | ||
| Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial | Q34798154 | ||
| Distinct internalization pathways of human amylin monomers and its cytotoxic oligomers in pancreatic cells | Q34982786 | ||
| Cardioprotection by controlling hyperamylinemia in a "humanized" diabetic rat model | Q35026344 | ||
| Amyloid beta-mediated cell death of cultured hippocampal neurons reveals extensive Tau fragmentation without increased full-length tau phosphorylation | Q35063341 | ||
| Association between amylin and amyloid-β peptides in plasma in the context of apolipoprotein E4 allele | Q35092684 | ||
| Cdk5: One of the links between senile plaques and neurofibrillary tangles? | Q35116571 | ||
| Misfolded proteins in Alzheimer's disease and type II diabetes. | Q35535599 | ||
| Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes | Q35855088 | ||
| Intermedin, a novel calcitonin family peptide that exists in teleosts as well as in mammals: a comparison with other calcitonin/intermedin family peptides in vertebrates | Q35914445 | ||
| Central nervous system and other effects | Q36402880 | ||
| G protein-coupled receptor signaling complexity in neuronal tissue: implications for novel therapeutics | Q36742422 | ||
| Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development | Q36925551 | ||
| Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease. | Q37297656 | ||
| Modulating receptor function through RAMPs: can they represent drug targets in themselves? | Q37371266 | ||
| Brainstem mechanisms of amylin-induced anorexia | Q37708537 | ||
| Alzheimer's disease: brain expression of a metabolic disorder? | Q37764520 | ||
| The role of G protein-coupled receptors in the pathology of Alzheimer's disease | Q37830311 | ||
| Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections | Q38014513 | ||
| The interaction of amylin with other hormones in the control of eating | Q38031993 | ||
| Alzheimer disease in 2020. | Q38057724 | ||
| Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology | Q38062765 | ||
| Metabolic basis of sporadic Alzeimer's disease. role of hormones related to energy metabolism. | Q38093190 | ||
| Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease? | Q38239648 | ||
| The therapeutics of Alzheimer's disease: where we stand and where we are heading | Q38392585 | ||
| Amylin: Pharmacology, Physiology, and Clinical Potential | Q38526856 | ||
| The amyloid cascade hypothesis: are we poised for success or failure? | Q38802617 | ||
| Amylin receptor ligands reduce the pathological cascade of Alzheimer's disease | Q38864016 | ||
| Amylin Treatment Reduces Neuroinflammation and Ameliorates Abnormal Patterns of Gene Expression in the Cerebral Cortex of an Alzheimer's Disease Mouse Model. | Q39136356 | ||
| Multiple target of hAmylin on rat primary hippocampal neurons | Q39288319 | ||
| Pramlintide Antagonizes Beta Amyloid (Aβ)- and Human Amylin-Induced Depression of Hippocampal Long-Term Potentiation | Q40107032 | ||
| Molecular physiology of the islet amyloid polypeptide (IAPP)/amylin gene in man, rat, and transgenic mice | Q40634226 | ||
| Glucoregulatory endocrine responses to intermittent exercise of different intensities: plasma changes in a pancreatic beta-cell peptide, amylin | Q40644046 | ||
| Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia | Q40897569 | ||
| Amylin, Calcitonin Gene-Related Peptide, Calcitonin, and Adrenomedullin: A Peptide Superfamily | Q41519839 | ||
| Learning and memory in the SAMP8 mouse | Q41716293 | ||
| β-Amyloid protein (Aβ) and human amylin regulation of apoptotic genes occurs through the amylin receptor | Q42494995 | ||
| Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats | Q42852579 | ||
| Suppression of IAPP fibrillation at anionic lipid membranes via IAPP-derived amyloid inhibitors and insulin | Q43163364 | ||
| Changes in differential functional magnetic resonance signals in the rodent brain elicited by mixed-nutrient or protein-enriched meals. | Q44073738 | ||
| Identification of hot regions of the Abeta-IAPP interaction interface as high-affinity binding sites in both cross- and self-association | Q44259570 | ||
| Dissecting the role of single regions of an IAPP mimic and IAPP in inhibition of Aβ40 amyloid formation and cytotoxicity. | Q44269390 | ||
| Electrophysiologically identified presynaptic mechanisms underlying amylinergic modulation of area postrema neuronal excitability in rat brain slices | Q44524571 | ||
| An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures | Q44564031 | ||
| Microglia in cerebellar plaques in Alzheimer's disease | Q44763168 | ||
| Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization | Q44833066 | ||
| Cross-amyloid interaction of Aβ and IAPP at lipid membranes | Q45332712 | ||
| Amylin Enhances Amyloid-β Peptide Brain to Blood Efflux Across the Blood-Brain Barrier | Q47095823 | ||
| Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study | Q47288123 | ||
| Selectively N-methylated soluble IAPP mimics as potent IAPP receptor agonists and nanomolar inhibitors of cytotoxic self-assembly of both IAPP and Aβ40. | Q47752480 | ||
| Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin | Q47849481 | ||
| Plasma amylin immunoreactivity and insulin resistance in insulin resistant relatives of patients with non-insulin-dependent diabetes mellitus | Q47983953 | ||
| Comparison of the effects of chronic central administration and chronic peripheral administration of islet amyloid polypeptide on food intake and meal pattern in the rat. | Q48114139 | ||
| Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. | Q48219387 | ||
| Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue | Q48233669 | ||
| Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor | Q48273018 | ||
| Role of microglia in plaque formation in senile dementia of the Alzheimer type. An immunohistochemical study | Q48421286 | ||
| Effect of active Aβ immunotherapy on neurons in human Alzheimer's disease | Q48445250 | ||
| Islet amyloid polypeptide and calcitonin gene-related peptide expression are upregulated in lumbar dorsal root ganglia after unilateral adjuvant-induced inflammation in the rat paw. | Q48581057 | ||
| Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. | Q48869814 | ||
| Altered verbal working memory process in patients with Alzheimer's disease: an fMRI investigation | Q49040993 | ||
| Quantitative neurohistological features of frontotemporal degeneration | Q49140415 | ||
| Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). | Q50864761 | ||
| Molecular characterization of the hetero-assembly of β-amyloid peptide with islet amyloid polypeptide. | Q50955641 | ||
| Involvement of the extracellular signal-regulated kinase 1/2 signaling pathway in amylin's eating inhibitory effect. | Q51364602 | ||
| Plasma amylin concentrations in fasted and fed rats quantified by a monoclonal immunoenzymometric assay. | Q51566975 | ||
| Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells. | Q53220157 | ||
| Activity of Pramlintide, Rat and Human Amylin but not Aβ1–42at Human Amylin Receptors | Q60516030 | ||
| Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5 | Q60603655 | ||
| Localization of calcitonin receptor mRNA in the mouse brain: coexistence with serotonin transporter mRNA | Q60728447 | ||
| Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease | Q68099264 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| G protein-coupled receptor | Q38173 | ||
| P304 | page(s) | 44-51 | |
| P577 | publication date | 2017-05-18 | |
| P1433 | published in | Neuroscience | Q15708571 |
| P1476 | title | Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease | |
| P478 | volume | 356 |
| Q48099438 | Activation of amylin receptors attenuates alcohol-mediated behaviours in rodents |
| Q89947927 | Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts |
| Q92747901 | Association of Plasma Amylin Concentration With Alzheimer Disease and Brain Structure in Older Adults |
| Q91883726 | Effects of Amylin Against Amyloid-β-Induced Tauopathy and Synapse Loss in Primary Neurons |
| Q58608075 | Fe Facilitates Endocytic Internalization of Extracellular Aβ and Enhances Aβ-Induced Caspase-3/Caspase-4 Activation and Neuronal Cell Death |
| Q92239665 | Melanocortin 4 receptor-mediated effects of amylin on thermogenesis and regulation of food intake |
| Q90700664 | Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin |
| Q92266507 | Short amylin receptor antagonist peptides improve memory deficits in Alzheimer's disease mouse model |
Search more.